MYDX is cash flow positive, which means the company's money will keep making money with keeping inventory on hand. Products that sold out will soon be available again. The fact that all the products are in demand is great future for MYDX. The AquaDX, OrganaDX, and AeroDX digital analyzers will be in the market soon and they each will be collecting valuable data for the company to leverage to third party interests. MYDX2 will soon follow as the premier household product for people who want to live a better, to actually live a better life as well as helping others by sharing health data. All this and then the MYDX medicinal cannabis smart vape pen which follows the company's business model by collecting valuable consumer data. All these products are expected to be on the market by end of year generating revenue with the exception of MYDX2, not sure if that is expected this year. Big pharma let MYDX be an early mover with revolutionary products including first to market a smart medicinal cannabis vape pen. Why would modern medicine choose anything less then the modern products? Why should big pharma risk entering cannabis market when they can just buy into MYDX?
I believe we see $100M+ market cap by end of year.
MYDX long and strong
AI
